伊立替康在小细胞肺癌化疗中所致重度不良反应的相关因素分析被引量：2

Analysis of Related Factors of Severe Adverse Reactions Induced by Irinotecan in Small Cell Lung Cancer Chemotherapy

下载PDF

导出

摘要目的:分析小细胞肺癌患者使用伊立替康发生Ⅲ度以上不良反应的相关因素。方法:对2015年12月~2018年11月共91例使用伊立替康的小细胞肺癌患者进行回顾性分析,探讨影响Ⅲ度以上不良反应的危险因素。结果:有放疗史和既往接受化疗次数是导致Ⅲ度以上中性粒细胞减少、腹泻和呕吐的危险因素。结论:这类患者需密切关注,加强观察,注意病情变化。 Objective: To analyze the related factors of above degree Ⅲ serious adverse reactions during the chemotherapy in patients with small cell lung cancer (SCLC) who received irinotecan. Methods: A retrospective analysis was performed on a total of 91 patients with SCLC who received irinotecan between December 2015 and November 2018, to explore the main factors affecting the occurrence of adverse reactions above grade Ⅲ. Results: The history of radiotherapy and frequency of chemotherapy were risk factors for neutropenia, diarrhea and vomit above grade Ⅲ. Conclusion: Patients with risk factors need close attention for changes of their conditions.

作者张亮周秋云张宇王洁丁红梓 ZHANG Liang;ZHOU Qiuyun;ZHANG Yu;WANG Jie;DING Hongzi(Department of Pharmacy,Nanjing Chest Hospital,School of Medicine,Southeast University,Nanjing 210029,China;Department of Respiratory,Nanjing Chest Hospital,School of Medicine,Southeast University,Nanjing 210029,China)

机构地区东南大学医学院附属南京胸科医院药学部东南大学医学院附属南京胸科医院呼吸内科

出处《药学与临床研究》 2019年第5期332-336,共5页 Pharmaceutical and Clinical Research

基金江苏省药学会-奥赛康医院药学基金（A2017013）南京市药学会-常州四药医院药学基金（2016YX015）

关键词肺癌伊立替康严重不良反应 Lung cancer Irinotecan Serious adverse reaction

分类号 R969.3 [医药卫生—药理学]

引文网络
相关文献

参考文献2

1周虹,吉顺莉,徐建华,陈先媛.顺铂联合伊立替康与依托泊苷对小细胞肺癌患者肺功能的影响及其疗效分析[J].肿瘤药学,2018,8(6):885-888. 被引量：10
2张晓光,张侠.盐酸伊立替康致迟发性腹泻作用机制及防治的研究进展[J].中国药物警戒,2012,9(9):535-538. 被引量：23

二级参考文献12

1孙华君,王翠松.伊立替康肠毒性预防研究进展[J].世界临床药物,2005,26(5):286-291. 被引量：23
2Zhou Y,Gwadry F G,Reinhold W C,et al.Transcriptional regula- tion of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose and time-dependent effects [J].Cancer Res,2002,62(6): 1688-95.
3Stein A,Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management [J]. Ther Adv Med Oncol. 2010,2(1):51-63.
4Hicks LD,Hyatt J L,Stoddard S,et al.lmproved,se-lective,human intestinal carboxylesterase inhibitors designed to nodulate 7-ethyl- 10-[4-(1-p iperidino)-l-piperidino] carbonyloxy-camp tothecin (irinotecan; CPT-11) toxicity[J]. M ed Chem, 2009, 52(12): 3742- 3752.
5Jessica M. van der Bol, Ron H.J Mathijssen, Geert-Jan M. Creemers, et al.A CYP3A4 Phenotype-Based Dosing Algorithm for Individ- ualized Treatment of Irinotecan [J]. Clin Cancer Res,2010,2(16): 736.
6Andrea M. Stringer ,Rachel J. Gibson ,Richard M,et al.Irinote- can-induced mucositis is associated with changes in intestinal mucins[J] .Cancer Chemother Pharmaco1,2009,64:123-132.
7Stringer A M,Gibson R J,Logann R M,et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat[J].Exp Biol MedJanuary ,2007,;232(1):96-106.
8I Antonello Di Paolo,Guido Bocci,Marialuisa Polillo,et al. Pharma- cokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity andToxicity[J]. CurrentDrug Metabolism, 2011,12: 932-943.
9Cecchin E,Innocenti F,D'Andrea M,et al.Predictive role of the UGTIA1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan[J].Clin. Oncol, 2009, 27(15):2457-2465.
10Ando, Y, Saka, H, Asai, G, et al. UGT1A1 genotypes and glu- curonidation of SN-38, the active metabolite of irinotecan[J].Ann. Oncol., 1998, 9(8):845-847.